COVID-19 vaccination: public preference and intention in Vietnam
Keywords:
COVID-19, vaccine preference, intention, barriers, motivations, hesitancy, VietnamAbstract
Backgrounds. Understanding public opinion in relation to vaccination is critical, as there are several COVID-19 vaccines approved for use in Vietnam. This study aimed to assess public COVID-19 vaccine preferences and intention in Can Tho, Vietnam.
Methods. An analytical cross-sectional study was performed between September 20 and October 20, 2021. in people aged 18 and over living in Can Tho, Vietnam, A questionnaire captured demographic information, vaccination intention, preference for vaccine selection, and barriers and motivations related to COVID-19 vaccination. Predictors for vaccination willingness among unvaccinated people were determined using multivariable logistic regression.
Results. Out of the proposed vaccines that have been approved by the Vietnam Ministry of Health, AstraZeneca (31.4%), Pfizer (23.5%), and Moderna (14.7%) were the most preferred by participants. Out of 1,470 respondents, 35.8% have received at least one vaccine dose, and of these, 76.9% intended to continue to receive vaccinations. Among the unvaccinated, 74.8% reported that they would be willing to complete the vaccination. Most participants stated that they would receive a COVID-19 vaccine if provided with adequate information on effectiveness and safety (92.7%). The possibility of side effects after vaccination (75.4%) was the most important barrier to vaccination. Education, health status, and prior flu-vaccination were associated with the intention to receive a COVID-19 vaccination among those who had not previously received one. Conclusions. Many unvaccinated adults were willing to receive a COVID-19 vaccination, with AstraZeneca being the preferred choice. These findings could help in the planning of vaccination campaigns to increase vaccination uptake in Vietnam.
References
1. World Health Organization (WHO). Novel Coronavirus (2019-nCoV): Situation Report - 1. 21 January 2020. Available on: https://www.who. int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019-ncov.pdf [Last accessed: 2022 July 19].
2. European Centre for Disease Prevention and Control (ECDC). Threat Assessment Brief: Rapid Increase of a SARS-CoV-2 Variant with Multiple Spike Protein Mutations Observed in the United Kingdom. 20 December 2020. Available on: https://www.ecdc.europa.eu/sites/default/ files/documents/SARS-CoV-2-variant-multiplespike-protein-mutations-United-Kingdom.pdf [Last accessed: 2022 July 19].
3. Public Health England. SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical Briefing 19. London: Wellington House; 2021.
4. Worldometers. COVID-19 Coronavirus Pandemic. 18 October 2021. Available on: https:// www.worldometers.info/coronavirus/ [Last accessed: 2021 October 18].
5. Nicola M, Alsafi Z, Sohrabi C, et al. The socioeconomic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020 Jun; 78: 185-293. doi: 10.1016/j.ijsu.2020.04.018. Epub 2020 Apr 17.
6. Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). Int J Mol Med. 2020 Aug; 46(2): 467-88. doi:
10.3892/ijmm.2020.4608. Epub 2020 May 18.
7. Calina D, Docea AO, Petrakis D, et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 2020 Jul; 46(1): 3-16. doi: 10.3892/ ijmm.2020.4596. Epub 2020 May 6.
8. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug 12; 385(7): 585-94. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
9. Musser JM, Christensen PA, Olsen RJ, et al.
Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID19 cases in Houston, Texas. medRxiv 2021: 2021.07.19.21260808. Now published in: Am J Pathol. 2022 Feb; 192(2): 320-31. doi: 10.1016/j.
ajpath.2021.10.019. Epub 2021 Nov 11.
10. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021:2021.07.07.21260122.
11. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv 2021: 2021.07.05.21260050. Now published in: Nat Commun. 2022; 13: 460. https://doi.org/10.1038/ s41467-022-28089-y.
12. Sheikh A, McMenamin J, Taylor B, et al. SARSCoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 Jun 26; 397(10293): 2461-2. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
13. Mlcochova P, Kemp S, Dhar MS, et al. SARSCoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. Nature. 2021; 599: 114-9.
https://doi.org/10.1038/s41586-021-03944-y.
14. Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv 2021: 2021.07.28.21261295. Clin Microbiol Infect.
2022 Apr; 28(4): 612.e1-612.e7. doi: 10.1016/j. cmi.2021.11.010. Epub 2021 Nov 23.
15. Riemersma KK, Grogan BE, Kita-Yarbro
A, et al. Shedding of Infectious SARSCoV-2 Despite Vaccination. medRxiv 2021: 2021.07.31.21261387.
16. COVID-19 Vaccine Tracker. 7 Vaccines Approved for Use by WHO. 18 October 2021. Available on https://covid19.trackvaccines.org/ [Last accessed: 2021 October 18].
17. Our World in Data. Coronavirus (COVID-19) Vaccinations. 18 October 2021. Available on https://ourworldindata.org/covid-vaccinations [Last accessed: 2021 October 18].
18. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel). 2021 Feb 16; 9(2): 160. doi: 10.3390/vaccines9020160.
19. Ministry of Health of Vietnam. The situation of COVID-19 epidemic in Vietnam. 18 October 2021. Available on https://moh.gov.vn/web/ministry-ofhealth [Last accessed: 2021 October 18].
20. Ministry of Health of Vietnam. 5K+VACCINE. 18 October 2021. Available on https://moh.gov. vn/web/ministry-of-health [Last accessed: 2021 October 18].
21. National COVID-19 Prevention and Control Technology Center. Covid-19 vaccine portal. 18 October 2021. Available on https:// english.mic.gov.vn/Pages/TinTuc/tinchitiet. aspx?tintucid=147700 [Last accessed: 2021 October 18].
22. Tran VD, Pak TV, Gribkova EI, et al. Determinants of COVID-19 vaccine acceptance in a high infection-rate country: a cross-sectional study in Russia. Pharm Pract (Granada). 2021 Jan-Mar; 19(1): 2276. doi: 10.18549/PHARMPRACT.2021.1.2276. Epub 2021 Mar 22.
23. Banik R, Islam MS, Pranta MUR, et al. Understanding the determinants of COVID-19 vaccination intention and willingness to pay: findings from a population-based survey in Bangladesh. BMC Infect Dis. 2021 Aug 31; 21(1): 892. doi: 10.1186/s12879-021-06406-y.
24. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020 Sep; 21(7): 977-82. doi: 10.1007/s10198-020-01208-6.
25. Alhinai ZA, Elsidig N. Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal? Int J Infect Dis. 2021 Sep; 110: 25860. doi: 10.1016/j. ijid.2021.06.040. Epub 2021 Jun 23.
26. Ball P. The lightning-fast quest for COVID vaccines — and what it means for other diseases. Nature 2021 Jan; 589(7840): 16-8. doi: 10.1038/ d41586-020-03626-1.
27. Yu Y, Lau JTF, Lau MMC, et al. Understanding the Prevalence and Associated Factors of Behavioral Intention of COVID-19 Vaccination Under Specific Scenarios Combining Effectiveness, Safety, and Cost in the Hong Kong Chinese General Population. Int J Health Policy Manag. 2021 Jan 18; doi: 10.34172/ijhpm.2021.02. Epub ahead of print..
28. MacDonald NE, Eskola J, Liang X, et al. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015 Aug 14; 33(34): 41614. doi:
10.1016/j.vaccine.2015.04.036. Epub 2015 Apr
17.
29. Magadmi RM, Kamel FO. Beliefs and barriers associated with COVID-19 vaccination among the general population in Saudi Arabia. BMC Public Health. 2021 Jul 21; 21(1): 1428. doi: 10.1186/s12889-021-11501-5.
30. Seale H, Heywood AE, McLaws ML, et al. Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC Infect Dis. 2010 Apr 19; 10(99). doi:
10.1186/1471-2334-10-99.
31. Alqudeimat Y, Alenezi D, AlHajri B et al. Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait. Med Princ Pract. 2021; 30(1): 26-71. doi: 10.1159/000514636. Epub 2021 Jan 22.
32. Shmueli L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health . 2021Apr 26; 21(1): 804. doi: 10.1186/s12889021-10816-7.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.